Drugs / HRS-6209
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07358377 | May 2026 → Apr 2027 expected | breast cancer | Atridia Pty Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07610148 | May → Jun 2026 overdue | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05781048 | Mar 2023 → Dec 2026 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07389733 | Mar 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06974929 | May 2025 → Dec 2026 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06679036 | Jan 2025 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-6209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06974929 ↗ |
| Action | Inhibit | “an oral cyclin-dependent kinases 4 (CDK4) inhibitor” NCT05582499 ↗ |
| Modality | Small molecule | “an oral cyclin-dependent kinases 4 (CDK4) inhibitor” NCT05582499 ↗ |
| Route | Oral | “Oral HRS-6209 capsules.” NCT06974929 ↗ |